ClinicalTrials.gg
TerminatedNCT00637403Updated Oct 17, 2016

Effect of Renal Impairment on the Pharmacokinetics, and Safety of Megestrol Acetate Concentrated Suspension

A Phase 1 interventional study of Megestrol acetate concentrated suspension 125 mg/mL and Megestrol acetate concentrated suspension 125 mg/mL in Healthy, sponsored by Par Pharmaceutical, Inc.. Terminated at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-10-17.

Sponsored by Par Pharmaceutical, Inc. (part of Par Health) · Phase 1 and Interventional

Why this study was terminated
Difficulty finding the required subject population

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
7
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 553 studies in Renal Insufficiency with a site in United States — 40 open to participants now, 57 under way, 3 of them phase 3. Renal Insufficiency · United States.

Enrollment
437th of 468
7 · median 32
Started
2006
with 17 others
Phase 1
232 of 553
14 open now
Registered
87th of 553
by date

Among the 553 studies in Renal Insufficiency with a site in United States, this one is the 437th largest by enrollment of the 468 interventional ones that give a count, is one of 18 that started in 2006, is one of 232 in phase 1, and was the 87th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

40 of the 553 studies in Renal Insufficiency with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 553 studies in Renal Insufficiency with a site in United States, or all of them as a file.
02

Study summary

To determine the pharmacokinetics and safety of megestrol acetate after a single oral 300 mg dose of megestrol acetate concentrated suspension in healthy subjects, and subjects with varying degrees of renal impairment

03

Conditions studied

  • Healthy

Keywords

  • renal impairment
  • end stage renal disease
  • megestrol acetate
  • pharmacokinetics
  • hemodialysis
  • renal dialysis
  • kidney failure, chronic
  • renal insufficiency
  • Megace ES
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy Subjects with Normal Renal Function

  1. ≥18 kg/m2 and ≤35 kg/m2
  2. Females of must use an adequate and reliable method of . females must be postmenopausal ≥1 year and have elevated serum FSH
  3. Able to provide written
  4. Normal renal function, defined as estimated (CLcr) >80 mL/min at screening

Subjects with Mild, Moderate, or Severe Renal Impairment or ESRD

Meet inclusion criteria 1 through 3 for healthy subjects and the following criteria:

  1. Renal impairment defined as creatinine clearance \<80 mL/min as determined using the Cockroft-Gault formula. Subjects grouped according to degree of renal dysfunction: mild (CLcr = >50 and ≤80 mL/min), moderate (CLcr = >30 and ≤50 mL/min), or severe (CLcr = ≤30 mL/min)
  2. Renal Impairment subjects must have evidence of stable renal impairment. Defined as having CLcr values within 25% of each other from 2 separately measured serum creatinine clearances using the Cockroft-Gault formula
  3. ESRD subjects require hemodialysis for at least 3 months
  4. Subjects with renal impairment or ESRD may have clinical laboratory test result deviations that are judged by the Investigator to be consistent with the renal condition of the subject or of no additional clinical significance for this study
  5. Subjects with renal impairment or ESRD, must have stable underlying medical conditions for at least 90 days prior to the start of study participation
  6. Renal impaired subjects may smoke up to 5 cigarettes per day

Exclusion criteria

Exclusion Criteria:

Healthy Subjects with Normal Renal Function

  1. (history of or active) cardiac, hepatic, renal, pulmonary, endocrine, neurological, infectious, gastrointestinal, hematologic, oncologic, or psychiatric disease that could put the subject at increased risk or could interfere with the objectives of the study
  2. Presence of any screening laboratory values outside the range of normal values and deemed clinically significant by the Investigator
  3. Use of a prescription drug within 14 days of study start, a non-prescription drug within 7 days of study start, or need of concomitant medication during the study
  4. Use of any drugs or herbal products known to inhibit or induce liver enzymes involved in drug metabolism (CYP P450) within 30 days prior to 1st dose
  5. History of allergic reaction or serum sickness to any drug or drug metabolites
  6. Whole blood donation within 56 days prior to the first MA-CS dose or plasma donation within 7 days prior to the first MA-CS dose
  7. Positive test for antibody or surface antigen (positive HIV or antibody for ESRD subjects are acceptable)
  8. Presence of drugs of abuse and/or alcohol
  9. Participation in another drug study within 30 days prior to the first MA-CS dose
  10. History of recent drug abuse or alcohol addiction during past 2 years
  11. Pregnant or breastfeeding
  12. Consumption of grapefruit containing foods and beverages within 7 days prior to the first MA-CS dose
  13. History of recurrent thromboembolic events, a thromboembolic event in past three months, or those still receiving long-term anticoagulation for thromboembolism

Subjects with Mild, Moderate, or Severe Renal Impairment or ESRD

Excluded if subjects meet exclusion criteria 4 through 13 for healthy subjects and the following criteria:

  1. Unstable disease defined as concurrent medical conditions that change significantly within 90 days
  2. Changes in concomitant medications within 14 days prior to first dose administration or expected changes during study participation
  3. Subjects with a renal transplant
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Active comparator
    I

    Megestrol acetate concentrated suspension in subjects with normal renal function

    Drug: Megestrol acetate concentrated suspension 125 mg/mL

  • Experimental
    II

    Megestrol acetate concentrated suspension in subjects with mild renal impairment

    Drug: Megestrol acetate concentrated suspension 125 mg/mL

  • Experimental
    III

    Megestrol acetate concentrated suspension in subjects with moderate renal impairment

    Drug: Megestrol acetate concentrated suspension 125 mg/mL

  • Experimental
    IV

    Megestrol acetate concentrated suspension in subjects with severe renal impairment

    Drug: Megestrol acetate concentrated suspension 125 mg/mL

  • Experimental
    V

    Megestrol acetate concentrated suspension in subjects with end stage renal disease

    Drug: Megestrol acetate concentrated suspension 125 mg/mL

Interventions

  • DrugMegestrol acetate concentrated suspension 125 mg/mL

    Drug page: Megestrol Acetate

    Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with normal renal function (CLcr \>80 mL/min)

    Also known as: Megace ES

  • DrugMegestrol acetate concentrated suspension 125 mg/mL

    Drug page: Megestrol Acetate

    Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with mild renal impairment (CLcr 50 - 80 mL/min)

    Also known as: Megace ES

  • DrugMegestrol acetate concentrated suspension 125 mg/mL

    Drug page: Megestrol Acetate

    Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with moderate renal impairment (CLcr 30 - \<50 mL/min)

    Also known as: Megace ES

  • DrugMegestrol acetate concentrated suspension 125 mg/mL

    Drug page: Megestrol Acetate

    Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with severe renal impairment (CLcr \<30 mL/min and not on hemodialysis)

    Also known as: Megace ES

  • DrugMegestrol acetate concentrated suspension 125 mg/mL

    Drug page: Megestrol Acetate

    Megestrol acetate concentrated suspension (125 mg/mL) administered orally as 2 single doses of 300 mg (2.4 mL x 125 mg/mL) each in subjects with end stage renal disease undergoing hemodialysis. Washout period of 21 days between each dose

    Also known as: Megace ES

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic blood samples

    Time frame: predose and serially through 264 hours post dose

  2. Urine collection

    Time frame: Predose and serially through 264 hours post dose

07

Study locations

1 site
  • SFBC International
    Miami, Florida 33181, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of May 2006 and a completion of May 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2008
First posted
Mar 18, 2008
Start
May 2006
Primary completionActual
May 2006
CompletionActual
May 2006
Last update
Oct 17, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00637403
Collaborators
Covance, SFBC Anapharm
Responsible party
Sponsor
First posted
Mar 18, 2008
Start date
May 2006
Primary completion
May 2006
Completion
May 2006
Last update
Oct 17, 2016

Study contacts

Kenneth C Lasseter, MD
principal investigator · SFBC International
Lynn D. Kramer, MD
study director · Par Pharmaceutical, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Megestrol Acetate

Start the discussion